托吡酯联合二甲双胍用于多囊卵巢综合征女性肥胖控制
这项随机双盲安慰剂对照试验纳入多囊卵巢综合征且体重指数≥30或≥27合并高血压、2型糖尿病或血脂异常的女性,在低热量饮食和二甲双胍基础上加用托吡酯或安慰剂。托吡酯组3个月和6个月体重下降幅度均大于安慰剂组,两组雄激素、血脂及心理社会评分均改善,托吡酯组感觉异常更常见。
要点
- 托吡酯联合二甲双胍加低热量饮食可使多囊卵巢综合征女性体重进一步下降。
- 3个月体重变化托吡酯组-3.4% vs 安慰剂组-1.6%,6个月-4.5% vs -1.4%,均P=.03。
- 托吡酯组感觉异常发生率23.3% vs 安慰剂组3.2%(P=.026)。
核心结论
- 在二甲双胍和低热量饮食基础上加用托吡酯可能是一种有效、低成本、易使用且安全的策略,用于多囊卵巢综合征女性的体重管理,不良反应轻微。
研究设计与样本
- 随机双盲安慰剂对照试验,纳入多囊卵巢综合征且体重指数≥30或≥27合并高血压、2型糖尿病或血脂异常的女性,在20 kcal/kg饮食及850 mg二甲双胍或既往二甲双胍方案基础上随机接受托吡酯或安慰剂。
- 二甲双胍+安慰剂组31例,二甲双胍+托吡酯组30例。
- 每4周评估人体测量、血压、改良Ferriman-Gallwey评分及不良事件,持续6个月。
- 主要终点为两组体重较基线的百分比变化;次要终点包括临床、心血管代谢、激素指标及心理社会特征的变化。
主要发现
- 二甲双胍+托吡酯组3个月平均体重下降-3.4% vs 二甲双胍+安慰剂组-1.6%(P=.03)。
- 二甲双胍+托吡酯组6个月平均体重下降-4.5% vs 二甲双胍+安慰剂组-1.4%(P=.03)。
- 两组雄激素、血脂及心理社会评分均改善。
- 6个月时体重下降≥3%的参与者改良Ferriman-Gallwey评分从8.4降至6.5(P=.026)。
- 二甲双胍+托吡酯组感觉异常更常见(23.3% vs 3.2%;P=.026)。
临床怎么用
- 作者认为,在二甲双胍和低热量饮食基础上加用托吡酯可能是多囊卵巢综合征女性体重管理的有效、低成本、易使用且安全的策略,不良反应轻微。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Polycystic ovary syndrome (PCOS) is often linked with obesity, and weight management can improve endocrine and cardiometabolic features. OBJECTIVE: This work aimed to evaluate the effects of adding topiramate (TPM) to metformin (MTF) on weight control and hormonal and metabolic outcomes in women with PCOS. METHODS: In a randomized, double-blind, placebo-controlled trial, participants with PCOS and body mass index of 30 or greater, or 27 or greater associated with hypertension, type 2 diabetes, or dyslipidemia followed a 20 kcal/kg diet in addition to 850 mg of MTF or a previous MTF regimen. They were randomly assigned to receive either TPM or placebo (P) alongside MTF. Anthropometric measurements, blood pressure, modified Ferriman-Gallwey score (mFGS), and adverse events were assessed every 4 weeks for 6 months. The primary end point was the percentage change in body weight from baseline in both groups. Secondary end points included changes in clinical, cardiometabolic, and hormonal parameters and psychosocial features. RESULTS: Thirty-one participants were in the MTF + P group and 30 in the MTF + TPM group. The MTF + TPM group showed greater mean weight loss at 3 months (-3.4% vs -1.6%; P = .03) and 6 months (-4.5% vs -1.4%; P = .03). Both groups had improved androgens, lipids, and psychosocial scores. Participants with 3% or greater weight loss at 6 months had improved mFGS (8.4 to 6.5; P = .026). Paresthesia was more common in the MTF + TPM group (23.3% vs 3.2%; P = .026). CONCLUSION: Combining TPM with MTF and a low-calorie diet may be an effective, low-cost, easy-to-use, and safe strategy for weight management in women with PCOS, with mild adverse effects.
引用
- Marchesan LB, da Silva TR, Spritzer PM, et al. Topiramate Added to Metformin for Obesity Control in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2025. PMID: 39271474. doi:10.1210/clinem/dgae637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。